Komori
Dividends4574TAIKO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Notice Regarding Receipt of Dividends from a Consolidated Subsidiary

The Company is scheduled to receive a dividend of HK$15 million (¥306 million) from a consolidated subsidiary. The dividend will be recorded as dividend income in the parent company's non-consolidated financial statements, but will have no impact on the consolidated financial statements.

Worth reading
—
Scored from 0 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
306
¥ million
Wording
Conditional
How definitive the wording is.

Dividend per share

Fiscal year ending December 2026
Total dividendsTotal amount payable to all shareholdersHK$15 million (¥306 million)
Dividend per share
ItemDetails
Total dividendsNot disclosed → HK$15 million (¥306 million)
Fiscal Period CoveredFiscal year ending December 2026
Items this document does not state (10)
Dividend per shareTotal Annual DividendsPrevious-period results (per share)Record dateEffective dateSource of dividendsBreakdown of Regular, Commemorative and Special DividendsPayout ratioDividend policyWhether Submission to the General Meeting of Shareholders Is Required

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The disclosure is being made because the matter meets the filing requirements for an extraordinary report under the Financial Instruments and Exchange Act and other applicable laws. The dividend received is expected to be recorded as dividend income in the non-consolidated financial statements, but because it is a dividend from a consolidated subsidiary, it will have no impact on consolidated results.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding Receipt of Dividends from a Consolidated Subsidiary | TAIKO PHARMACEUTICAL CO.,LTD. (4574) timely disclosure | Komori